Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amicus Therapeutics reports robust revenue growth and eyes AT-GAA launch

Amicus Therapeutics showcased strong performance and growth prospects for Galafold and AT-GAA therapy.
The company aims for non-GAAP profitability in 2023, focusing on key strategic priorities and market expansion.
Challenges include profitability targets, regulatory approvals, and managing production costs for new therapies.
Opportunities lie in the anticipated AT-GAA launch, geographic market expansion, and continued revenue growth.

Amicus Therapeutics reports robust Q1 performance and eyes AT-GAA FDA approval

Amicus Therapeutics delivered strong Q1 results, focusing on revenue growth, regulatory milestones, and financial stability. The company's strengths lie in Galafold sales growth, positive patient outcomes with AT-GAA, and market opportunities in Pompe disease treatment. Challenges include scaling up patient numbers and transitioning manufacturing facilities, while opportunities exist in market expansion and physician engagement.

Amicus Therapeutics excels in Q2, eyes global expansion and profitability

Amicus Therapeutics demonstrates strong financial growth, focusing on expanding market presence and achieving non-GAAP profitability. The company's performance with Galafold and progress on regulatory filings position it well for future success, despite facing challenges in patient transitions and leadership changes.

Amicus Therapeutics reports robust Q3 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q3 2023, with revenue growth and profitability on track, supported by strategic investments and market expansion efforts.
The company's focus on patient-centric approaches, physician engagement, and global market penetration positions it well for future growth and success.
While facing challenges in gene therapy programs and revenue dynamics, Amicus is actively addressing these issues and leveraging opportunities in expanding markets and innovative therapies.
Overall, Amicus Therapeutics remains well-positioned in the biopharmaceutical industry, with a strong foundation for continued growth and impact in treating rare diseases.

Amicus Therapeutics reports strong Q4 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q4 2023, aiming for sustained growth and profitability in 2024 through strategic priorities and successful product launches.
The company faces challenges in forecasting seasonal trends and expanding payer coverage, yet opportunities lie in maximizing patient therapy, leveraging AI advancements, and broadening market reach.
With a focus on rare disease treatments and market penetration, Amicus is poised for growth and intervention strategies to address patient variability and drive revenue in 2024.

Amicus Therapeutics reports strong Q1 performance and growth opportunities

Amicus Therapeutics delivered strong Q1 2024 results, driven by Galafold's performance and a focus on expanding patient numbers for Pombiliti and Opfolda.
While facing challenges such as increased operating expenses and potential manufacturing issues, the company remains confident in its growth trajectory and supply capabilities.
Opportunities lie in revenue expansion, leveraging positive feedback for Pombiliti and Opfolda, and enhancing real-world evidence generation through registries.
Efforts to streamline treatment processes and establish new standards of care position Amicus for continued growth and impact in the rare disease space.

Amicus Therapeutics (FOLD) reports robust Q3 earnings and growth strategies

Amicus Therapeutics (FOLD) delivered strong financial performance in Q3 2024, driven by robust Galafold revenue and strategic focus on patient access.
While facing competitive pressures and regulatory challenges, the company aims to sustain growth through pipeline development and expense management.
Raising financial guidance and exploring accelerated approval opportunities position Amicus for continued success in the genetic medicine market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Washington, D.C., July 24, 2024 (GLOBE NEWSWIRE) -- Today, the en banc U.S. Court of Appeals for the Fifth Circuit ruled in Consumers' Research v.

In NCLA Amicus Win, Fifth Circuit Rules Against FCC's Unlawful Control of Universal Service Fund

Corner Post, Inc. v. Board of Governors of the Federal Reserve System Corner Post, Inc. v. Board of Governors of the Federal Reserve System

In NCLA Amicus Win, Supreme Court Upholds Small Business's Right to Judicial Review

Securities and Exchange Commission v. George R. Jarkesy, Jr. and Patriot28, L.L.C. Securities and Exchange Commission v. George R. Jarkesy, Jr. and Patriot28, L.L.C.

In NCLA Amicus Win, Supreme Court Restores Americans' Rights to Trial by Jury

State of Texas; State of Mississippi; State of Louisiana v. Janet Yellen, Richard K. Delmar, U.S. Department of the Treasury, United States of America State of Texas; State of Mississippi; State of Louisiana v. Janet Yellen, Richard K. Delmar, U.S. Department of the Treasury, United States of America

In NCLA Amicus Win, Fifth Circuit Upholds Permanent Block on Treasury's Illegal State Tax Cut Ban

Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB

In NCLA Amicus Win, Supreme Court Overturns NLRB-Specific Preliminary Injunction Standard

Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture

In NCLA Amicus Win, Tenth Circuit Clears Path to Toppling Intrusive Dog Kennel Inspection Regime

National Association of Private Fund Managers, et al. v. Securities and Exchange Commission National Association of Private Fund Managers, et al. v. Securities and Exchange Commission

In NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private Funds

PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T.

Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Aurinia Pharmaceuticals

Voyager Therapeutics

Today, we take a look at three promising biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability, and the other is cash rich and has several partnerships with large pharma companies. We profile all three of these names with favorable risk/reward profiles in the paragraphs below.

3 Biotech Names Under $10 I Own

Amicus Therapeutics has recently seen its shares slide under $10, despite strong revenue growth. The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seeing good sales traction. Analyst firms are also largely positive on the company's prospects.

Amicus Therapeutics: Too Cheap At Under $10 A Share

Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - CBO Jeff Castelli - CDO Simon Harford - CFO Conference Call Participants Anupam Rama - JPMorgan Ellie Merle - UBS Kristen Kluska - Cantor Fitzgerald Tazeen Ahmad - Bank of America Operator Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' First Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Amicus Therapeutics, Inc. (FOLD) Q1 2024 Earnings Call Transcript

Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.18 per share a year ago.

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold ® Guidance on Continued Strong Demand Strong Pombiliti ® + Opfolda ® Launch with Increasing Rate of Commercial Patient Starts Reiterating Full-Year Non-GAAP Profitability Projected in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.

Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates

PRINCETON, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2024 Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024, at 1:40 p.m. P.T.

Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2024.

Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year's report highlights the strength of the Company's corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensuring broad and equitable access to our innovative therapies, fostering an inclusive culture to ensure equal representation and participation for all, and maintaining our leadership of strong business ethics and integrity.

Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report

PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024

Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

Amicus Therapeutics should deliver strong topline growth with expanding margins and increasing cash flows in 2024.

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript

Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.19 per share a year ago.

News for Amicus Therapeutics Stock (FOLD)